3 days Ago By ABMN Staff
Medtronic ( NYSE:MDT – Free Report ) had its target price reduced by JPMorgan Chase & Co. from $99.00 to $96.
00 in a research report released on Friday morning. JPMorgan Chase & Co. currently has a neutral rating on the medical technology company’s stock.
A number of other analysts have also commented on MDT. Oppenheimer boosted their target price on Medtronic from $92.00 to $94.
00 and gave the company a “market perform” rating in a research report on Wednesday, August 21st. Stifel Nicolaus boosted their price objective on Medtronic from $85.00 to $87.
00 and gave the stock a “hold” rating in a report on Wednesday, August 21st. Needham & Company LLC reissued a “hold” rating on shares of Medtronic in a report on Friday, October 25th. Royal Bank of Canada raised Medtronic from a “sector perform” rating to an “outperform” rating and boosted their price objective for the stock from $98.
00 to $105.00 in a report on Thursday, October 10th. Finally, Citigroup boosted their price objective on Medtronic from $85.
00 to $92.00 and gave the stock a “neutral” rating in a report on Tuesday, October 1st. One research analyst has rated the stock with a sell rating, nine have assigned a hold rating, six have assigned a buy rating and one has issued a strong buy rating to the company.
Based on data from MarketBeat.com, the stock currently has an average rating of “Hold” and a consensus target price of $95.80.
Check Out Our Latest Research Report on MDT Medtronic Stock Performance Medtronic ( NYSE:MDT – Get Free Report ) last issued its earnings results on Tuesday, August 20th. The medical technology company reported $1.23 EPS for the quarter, beating analysts’ consensus estimates of $1.
20 by $0.03. Medtronic had a return on equity of 13.
68% and a net margin of 12.06%. The business had revenue of $7.
97 billion during the quarter, compared to analyst estimates of $7.90 billion. During the same period in the previous year, the company posted $1.
20 EPS. The firm’s revenue was up 3.4% compared to the same quarter last year.
On average, research analysts anticipate that Medtronic will post 5.44 earnings per share for the current fiscal year. Hedge Funds Weigh In On Medtronic Hedge funds and other institutional investors have recently modified their holdings of the business.
Fortitude Family Office LLC purchased a new position in Medtronic in the third quarter valued at approximately $27,000. Darwin Wealth Management LLC purchased a new position in Medtronic in the third quarter valued at approximately $27,000. Highline Wealth Partners LLC purchased a new position in Medtronic in the third quarter valued at approximately $27,000.
J. Stern & Co. LLP purchased a new position in Medtronic in the third quarter valued at approximately $30,000.
Finally, Lynx Investment Advisory purchased a new position in Medtronic in the second quarter valued at approximately $28,000. Hedge funds and other institutional investors own 82.06% of the company’s stock.
About Medtronic ( Get Free Report ) Medtronic plc develops, manufactures, and sells device-based medical therapies to healthcare systems, physicians, clinicians, and patients worldwide. Its Cardiovascular Portfolio segment offers implantable cardiac pacemakers, cardioverter defibrillators, and cardiac resynchronization therapy devices; cardiac ablation products; insertable cardiac monitor systems; TYRX products; and remote monitoring and patient-centered software. Featured Stories Receive News & Ratings for Medtronic Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Medtronic and related companies with MarketBeat.
com's FREE daily email newsletter ..
